TG1050, a Novel Immunotherapeutic to Treat Chronic Hepatitis B, can Control HBsAg and Provoke HBsAg Seroconversion in HBV-Persistent Mouse Models


Karine Lélu, et al.
EASL Liver Congress 2015, Vienna-23th April 2015
Download the poster here
Poster Presentation